Treating Myelodysplastic Syndrome by Downregulating the RAS Pathway with Dr. Steven Fruchtman Onconova Therapeutics TRANSCRIPT

 
シェア
 

Manage episode 267708219 series 99915
著作 Karen Jagoda の情報はPlayer FM及びコミュニティによって発見されました。著作権は出版社によって所持されます。そして、番組のオーディオは、その出版社のサーバから直接にストリーミングされます。Player FMで購読ボタンをタップし、更新できて、または他のポッドキャストアプリにフィードのURLを貼り付けます。

Steven M. Fruchtman, M.D., President and Chief Executive Officer, Onconova Therapeutics discusses Rigosertib, a drug that has the potential to downregulate the RAS pathway, the most commonly mutated gene in cancer. Rigosertib is a proprietary phase 3 small molecule, currently being evaluated in second-line treatment of patients with higher-risk myelodysplastic syndrome (MDS) and refractory higher-risk MDS patients. Also known as pre-leukemia, MDS is a cancer of the bone marrow stem cell and the mission of Onconova is to prolong the lives of those suffering from this disease.

@Onconova_ONTX

#cancer #oncology #RAS #MDS #PreLeukemia #Leukemia $ONTX

Onconova.com

Listen to the podcast here

441 つのエピソード